恩替卡韦联合肝复乐胶囊治疗慢性乙型肝炎肝纤维化80例疗效观察

Clinical efficacy of entecavir combined with Ganfule capsules in treatment of 80 cases of chronic hepatitis B with hepatic fibrosis

目的探究恩替卡韦(entecavir,ETV)联合肝复乐胶囊治疗慢性乙型肝炎肝纤维化的临床疗效。方法选取慢性乙型肝炎肝纤维化患者160例,随机分为2组。对照组80例,采用单一ETV治疗,联合组80例,采用ETV联合肝复乐胶囊治疗,疗程均为3个月。观察两组患者治疗前和治疗后肝功指标、乙型肝炎病毒血清学标志物、HBV DNA载量、肝纤维化指标及肝脏影像学等变化。结果治疗后,联合组ALT水平、HBe Ag血清学转换率、肝纤维化指标(HA、LN、PC-Ⅲ、Ⅳ-C)、门静脉内径及脾脏厚度均显著低于对照组(P值分别为0.0048、0.0001、0.0019、0.0043、0.0017、0.0002、0.0025和0.0020);HBV DNA低于检测下限率、AST、TBil、ALB、PT与对照组相比无统计学差异(P值分别为1.2922、0.0598、0.0751、0.0972和0.9916)。结论采用ETV结合肝复乐胶囊联合治疗慢性乙型肝炎肝纤维化临床效果良好,值得广泛推广应用。

Objective To investigate the clinical efficacy of entecavir（ETV） combined with Ganfule capsules in treatment of chronic hepatitis B patients with hepatic fibrosis. Methods Total of 160 chronic hepatitis B patients with hepatic fibrosis were randomly divided into two groups. The control group（80 cases） were only treated with ETV, the combination group（80 cases） were treated with ETV combined with Ganfule capsules. The HBV DNA and HBe Ag negative rate, serum fibrosis markers（serum HA, LN, PC-Ⅲ, Ⅳ-C）, liver function, markers of hepatitis B virus and liver imaging changes before and after treatment of the two groups were compared. Results After treatment, the HBV DNA negative rate, ALT levels, HBe Ag negative rate, serum fibrosis markers（serum HA, LN, PC-Ⅲ, Ⅳ-C）, diameter of portal vein and the thickness of the spleen in combination group were significantly lower than those of the control group（P = 0.0048, 0.0001, 0.0019, 0.0043, 0.0017, 0.0002, 0.0025, 0.0020）. HBV DNA negative rate, AST, TBil, ALB and PT in combination group had no statistical differences compared with the control group（P = 1.2922, 0.0598, 0.0751, 0.0972, 0.9916）. Conclusion The clinical effects of ETV combined with Ganfule capsules in treatment of chronic hepatitis B patients with liver fibrosis is worthy of widely applying.